The ResAppDx-EU, the world’s first smartphone-based diagnostic test for acute pediatric respiratory disease, has received CE Mark certification as a Class II-a medical device, according to the company.
ResAppDx-EU is a mobile software application to be used by clinicians for the diagnosis of lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease and bronchiolitis in infants and children. The software uses machine learning algorithms that analyze a patient’s cough sounds to diagnose disease. ResAppDx-EU is a software-only solution that runs on an off-the-shelf smartphone and does not require any additional hardware or accessories.
The CE Mark approval was supported by data collected in ResApp’s Breath Easy pediatric clinical study. The Breath Easy study was a double-blind, prospective study which evaluated the efficacy of ResApp’s cough-based diagnosis algorithms in diagnosing acute respiratory disease in children. The study collected data from 585 patients and demonstrated that ResApp’s algorithms had excellent agreement with a clinical diagnosis. Results from the study were recently published in the peer-reviewed journal Respiratory Research.
“We are very excited about receiving our first regulatory approval for ResAppDx-EU, our flagship acute diagnostic product,” said Tony Keating, CEO and Managing Director of ResApp. “This is our biggest achievement yet and results from many years of hard work by our dedicated team. For the first time clinicians in Europe will have access to a rapid and accurate diagnostic test for the most commonly seen acute respiratory conditions in children. ResAppDx-EU has the potential to have far-reaching benefits in the healthcare system and we will now rapidly move ahead with our European commercialization strategy.”
CE Mark certification will facilitate further regulatory submissions in Australia, Canada and Singapore. In April, ResApp submitted a De Novo classification request to the US Food and Drug Administration which is currently pending review.